Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRACTION: Fedratinib and Nivolumab in Myelofibrosis After JAK Inhibitor Failure
2024-513953-64-00Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fedratinib and nivolumab in primary myelofibrosis (PMF) and myelofibrosis (MF), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Best response rate within 12 treatment cycles. Started Oct 2024; status: completed.
02
Drugs
fedratinibnivolumab
03
Conditions
primary myelofibrosis (PMF)myelofibrosis (MF)
Beyond the preview
Go deeper on 2024-513953-64-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513953-64-00.